Analysts Set Average Price Target of $112.19 for Bio-Techne Corporation

Trending News 🌥️

Bio-techne Corporation Stock Fair Value – BIO-TECHNE ($NASDAQ:TECH): Bio-Techne Corporation is a biotechnology company that specializes in the production of proteins and antibodies for research, therapeutic and diagnostic use. Its extensive portfolio of products and services span a range of scientific disciplines, including cell biology, molecular biology, immunology and proteomics. Recently, analysts have set an average price target of $112.19 for Bio-Techne Corporation’s stock. This means that analysts expect the stock to reach, or even exceed, that price in the near future. Such an increase in stock value would be a great reward for investors who have been loyal to the company over the years. Analysts cite the company’s strong financial performance over the past few years, as well as its innovative product offerings and strategic partnerships with other companies in the industry. They also point to Bio-Techne Corporation’s growing presence in Asia, which should help to expand its customer base and increase its revenues. Bio-Techne Corporation has also made significant investments in research and development, which has allowed it to stay ahead of the competition and keep its products at the forefront of the industry.

Additionally, its management team is highly experienced, with years of expertise in biotechnology and other related fields. All of these factors have combined to create an attractive stock option for investors. Overall, Bio-Techne Corporation is an excellent investment opportunity for those looking to capitalize on the potential of this biotechnology giant. With an average price target of $112.19, analysts are confident that Bio-Techne’s stock will continue to rise in the future.

Price History

So far, news regarding the company has been mostly positive. On Friday, Bio-Techne Corporation stock opened at $81.3 and closed at $80.7, representing a decrease of 1.5% from its prior closing price of $82.0. The company manufactures, sells, and distributes biotechnology reagents and products to researchers in the fields of immunology, protein biology, genomics, and cell biology. Bio-Techne has a broad portfolio of products and services, which include antibodies, proteins, peptides, and nucleic acids; cell culture media; ELISA kits; PCR products; flow cytometry reagents; gene expression assays; and other products.

The company recently announced its second quarter financial results. The company also announced that it will be launching several new products in the near future. Investors should keep an eye on the company’s financial performance and product launches to determine whether or not the stock is a good investment opportunity. Live Quote…

About the Company

VI Analysis – Bio-techne Corporation Stock Fair Value

BIO-TECHNE CORPORATION is a company that has great growth potential according to its fundamentals. This is easily seen through the VI app, which simplifies the analysis of the company’s performance. VI Line reveals that the intrinsic value of BIO-TECHNE CORPORATION shares is around $103.3, yet the stock is currently trading at only $80.7. This means the stock is undervalued by 22%, presenting a great opportunity for investors. The company’s fundamentals reflect this great potential, as evidenced by its strong financials, strong dividend payments, and increasing sales and profits. BIO-TECHNE CORPORATION’s balance sheet is healthy with a low debt to equity ratio, indicating that the company can easily handle any financial issues that may arise. Additionally, its management team is experienced and knowledgeable in the industry, helping to ensure that the company continues to grow. Overall, BIO-TECHNE CORPORATION is a great investment option for those looking for long-term potential. Its fundamentals reflect its growth potential and its stock is currently undervalued by 22%. Investors should take advantage of this opportunity now before it passes them by. More…

VI Peers

In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.

– Proteomics International Laboratories Ltd ($ASX:PIQ)

Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.

– AEterna Zentaris Inc ($TSX:AEZS)

Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.

– AXIM Biotechnologies Inc ($OTCPK:AXIM)

AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.

The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.

The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.

Summary

Investing in Bio-Techne Corporation can be a great opportunity for those looking to diversify their portfolio. Bio-Techne Corporation is a biotechnology company that focuses on providing innovative products and services to life science researchers, clinical researchers, and other customers. It offers a wide range of reagents, antibodies, proteins, immunoassays, and other tools to help researchers pursue their studies. Bio-Techne Corporation has been performing well in recent years, as evidenced by its strong financials and the analysts’ average price target of $112.19. Its revenue has grown steadily and its net income has been increasing at an impressive rate. Furthermore, it has a strong balance sheet with no long-term debt, which shows its ability to manage its cash flow efficiently. The company is also growing its product portfolio through acquisitions and partnerships with other biotechnology companies. This helps it to expand its growth opportunities and provide its customers with access to new products and services.

Additionally, Bio-Techne Corporation is investing in research and development, which is helping it to stay ahead of the competition and develop innovative products for its customers. Overall, Bio-Techne Corporation is an attractive investment opportunity for those looking for a solid biotech company with an impressive track record and a strong balance sheet. Its financials, product portfolio, and acquisitions show that it is well-positioned to continue its positive performance in the future.